Neovasc Inc. Reports Results of Annual General Meeting of Shareholders
September 03 2020 - 4:34PM
via NEWMEDIAWIRE -- Neovasc Inc. (“
Neovasc” or the
“
Company”) (NASDAQ, TSX: NVCN) is pleased to
announce the results of the votes on matters considered at its
Annual General Meeting of Shareholders held on September 3, 2020 in
Vancouver, B.C. (the “
Meeting”).
At the Meeting, the shareholders of the Company
(the “Shareholders”) re-elected board members
Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko
and Fred Colen to serve in office until the next annual meeting or
until their successors are duly elected or appointed. Detailed
results of the voting in respect of the election of directors are
as follows:
Nominee |
Votes For |
% Votes For |
Votes Withheld |
% Votes Withheld |
Steven Rubin |
5,744,656 |
80.53 |
1,388,972 |
19.47 |
Paul Geyer |
6,632,055 |
92.97 |
501,573 |
7.03 |
Doug Janzen |
6,702,438 |
93.96 |
431,190 |
6.04 |
Norman Radow |
6,693,984 |
93.84 |
439,644 |
6.16 |
Alexei Marko |
6,497,336 |
91.08 |
636,292 |
8.92 |
Fred Colen |
6,613,038 |
92.70 |
520,590 |
7.30 |
At the Meeting, the Shareholders also approved
the Company’s share unit plan (78.00% of votes cast in favour), the
Company’s previous grants of share units (77.78% of votes cast in
favour) and re-appointed Grant Thornton LLP, Chartered Accountants
as auditors of the Company.
About Neovasc Inc.Neovasc is a
specialty medical device company that develops, manufactures and
markets products for the rapidly growing cardiovascular
marketplace. Its products include Reducer, for the treatment of
refractory angina, which is not currently commercially available in
the United States and has been commercially available in Europe
since 2015, and Tiara, for the transcatheter treatment of mitral
valve disease, which is currently under clinical investigation in
the United States, Canada, Israel and Europe. For more information,
visit: www.neovasc.com.
InvestorsMike CavanaughWestwicke/ICR Phone:
+1.646.877.9641Mike.Cavanaugh@westwicke.com
MediaSean LeousWestwicke/ICR Phone:
+1.646.677.1839Sean.Leous@icrinc.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When used
herein, the words "expect", "anticipate", "estimate", "may",
"will", "should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements may involve, but are not limited to, expectations as to
the growing cardiovascular marketplace. Forward-looking statements
are based on estimates and assumptions made by the Company in light
of its experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors that the Company believes are appropriate in the
circumstances. Many factors could cause the Company's actual
results, performance or achievements to differ materially from
those expressed or implied by the forward looking statements,
including those described in the "Risk Factors" section of the
Company's Annual Report on Form 20-F and in the Management's
Discussion and Analysis for the three months ended June 30, 2020
(copies of which may be obtained at www.sedar.com or www.sec.gov).
These factors should be considered carefully, and readers should
not place undue reliance on the Company's forward-looking
statements. The Company has no intention and undertakes no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Sep 2023 to Sep 2024